Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance

被引：0
|
作者：
Hirotsugu Uemura
Yoshihiko Tomita
Norio Nonomura
Kenji Yoshizaki
Takafumi Nakao
Nobuo Shinohara
机构：
[1] Kindai University Faculty of Medicine,Department of Urology
[2] Niigata University Graduate School of Medical and Dental Sciences,Department of Urology, Department of Molecular Oncology
[3] Osaka University Graduate School of Medicine,Department of Urology
[4] Ono Pharmaceutical Co.,Safety Management Pharmacovigilance Division
[5] Ltd.,Department of Renal and Genitourinary Surgery
[6] Hokkaido University Graduate School of Medicine,undefined
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Effectiveness; Japan; Nivolumab; Post-marketing surveillance; Safety; Un-resectable or metastatic renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1061 / 1067
页数：6
相关论文
共 50 条
  • [21] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Furuse, Junji
    Izumi, Namiki
    Motomura, Kenta
    Inaba, Yoshitaka
    Katamura, Yoshio
    Kondo, Yasuteru
    Yabushita, Kazuhisa
    Motoyoshi, Katsuaki
    Kudo, Masatoshi
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
  • [22] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Junji Furuse
    Namiki Izumi
    Kenta Motomura
    Yoshitaka Inaba
    Yoshio Katamura
    Yasuteru Kondo
    Kazuhisa Yabushita
    Katsuaki Motoyoshi
    Masatoshi Kudo
    [J]. Drugs - Real World Outcomes, 2023, 10 : 195 - 205
  • [23] Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan
    Hayashi, Nobukazu
    Hayama, Koremasa
    Takahashi, Kenzo
    Kurokawa, Ichiro
    Okazaki, Masateru
    Kashiwagi, Tomoko
    Iwashita, Eri
    Terui, Tadashi
    [J]. JOURNAL OF DERMATOLOGY, 2022, 49 (04): : 411 - 421
  • [24] Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan.
    Harada, H.
    Watarai, Y.
    Uchida, J.
    Kamisawa, O.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 675 - 675
  • [25] Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance
    Ohe, Y.
    Gemma, A.
    Nakagawa, K.
    Yamamoto, N.
    Saito, T.
    Akamatsu, A.
    Kuwano, K.
    Nakanishi, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [26] Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study
    Hide, Michihiro
    Fukunaga, Atsushi
    Suzuki, Takayuki
    Nakamura, Noriko
    Kimura, Mine
    Sasajima, Takayoshi
    Kiriyama, Junna
    Igarashi, Atsuyuki
    [J]. ALLERGOLOGY INTERNATIONAL, 2023, 72 (02) : 286 - 296
  • [27] Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance
    Uhara, Hisashi
    Kiyohara, Yoshio
    Isei, Taiki
    Nagase, Kotaro
    Kambe, Anzu
    Sato, Masashi
    Tanaka, Yutaro
    Yamazaki, Naoya
    [J]. JOURNAL OF DERMATOLOGY, 2024, 51 (04): : 475 - 483
  • [28] Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
    Tanabe, Nobuhiro
    Ogo, Takeshi
    Hatano, Masaru
    Kigawa, Ayaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    [J]. PULMONARY CIRCULATION, 2020, 10 (03)
  • [29] Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance
    Saeki, Hidehisa
    Fujita, Hiroyuki
    Suzuki, Katsuhisa
    Arima, Kazuhiko
    [J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 78 - 87
  • [30] Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Fukamizu, Yuji
    Osawa, Takehiko
    Kikui, Hidekazu
    Utsugisawa, Kimiaki
    [J]. NEUROLOGY, 2022, 98 (18)
12345